PEPTONIC medical : Year end report Jan Dec 2023

YEAR END REPORT

January - December 2023

PEPTONIC medical AB (public) org nr 556776-3064

GROUP

2023 FOURTH QUARTER (October-December)

• Sales of products 6,786 (10,191) KSEK
• Adjusted gross profit: 3,709 (5,313) KSEK, 55% (52%) after comparison affecting items of -3,016(-1,011) KSEK **
• Operating profit: -19,572(-6,890) KSEK
• Adjusted operating profit: -11,885(-5,289) KSEK after comparison affecting items of -7,687 (- 1,011) KSEK *
• Earnings per share: -0.02(-0.03) SEK

2023 FULL YEAR (January-December)

1. • Sales of products 37,118 (43,634) KSEK
   • Adjusted gross profit: 19,311 (23,394) KSEK, 52% (54%) after comparison affecting items of - 3,016 (-1,011) KSEK *
   • Operating profit: -41,186(-33,606) KSEK
   • Adjusted operating profit: -33,499(-33,606) KSEK after comparison affecting items of -7,687 (0) KSEK *
   • Earnings per share: -0.04(-0.15) SEK
2. one-offitems affecting comparability -7,687 KSEK consisting of personnel restructuring costs (-1,800 KSEK), write-down of receivable in the USA (-885 KSEK), write-down of oxytocin patent in menopause (- 1,986 KSEK), and (**) adjustment of obsolescence (-3,016 KSEK).

YEAR END REPORT, 2023

1

IMPORTANT EVENTS DURING THE PERIOD

Peptonic Medical AB announced the following:

• An exclusive agreement regarding VagiVital AL's self-test for detecting amniotic fluid leakage has been signed with Savyon Diagnostics for the Israeli market.
• A distribution agreement has been signed with Walmart to sell Peptonic's self-test for bacterial vaginosis. The test will be sold under Walmart's own brand.
• The company has received its first order from Windsor Pharmaceuticals for Peptonic's vaginal self-tests VagiVital AL Sense and VagiVital VS Sense Pro. The products will be sold in Central America under Windsor's own brand Amniotest.
• A non-exclusive agreement regarding VagiVital VS Pro has been signed with Al Fortune Medical Equipment for the United Arab Emirates.
• A positive outcome from the subscription of options of series TO3. The successful subscription options of series TO3, provided Peptonic Medical with approximately 7.6 MSEK before issuance costs.
• The Swedish Companies Registration Office has registered the merger between Peptonic Medical AB and Pharmiva AB (publ).
• The board of directors of Peptonic Medical AB convened an extraordinary general meeting on January 11, 2024.

IMPORTANT EVENTS AFTER THE PERIOD

Peptonic Medical AB announced the following:

• Launch of two new products (VagiVital Menopause FSH Test and VagiVital Urinary Tract Infection Self Test) in the domestic market of Sweden.
• The Board conducted a strategic restructuring of the company's management, appointing Anna Linton as the new CEO.
• An extraordinary general meeting was held where Kristina Ingvar was elected to the company's board.
• Subsidiary Lune Group Oy filed for bankruptcy due to increased competition and negative operating results.
• The company announced that CFO Albert Lindgren is leaving the company.
• An exclusive distribution agreement for VagiVital and Venriva was signed in the Benelux region.
• The subscription price for series TO4 subscription options was set at 0.028 SEK.
• The Board decided, subject to approval from the shareholders' meeting, on a rights issue of units totaling approximately 61.4 MSEK.

YEAR END REPORT, 2023

2

LETTER FROM THE CEO

With boundless enthusiasm and genuine humility, I have stepped into the role of CEO. I eagerly anticipate, alongside our dedicated team and board, propelling Peptonic Medical to solidify its position as a leading player in intimate self-care. This endeavor transcends mere job responsibilities- it's a deep commitment to advancing women's health.

Being a part of Peptonic Medical's devoted work, empowering women to guard their intimate health, is meaningful. Our portfolio and offerings aren't just unique, they also redefine intimate self-care. It's not just about products; it's about allowing women to diagnose, treat, and prevent intimate medical conditions on their own independently and effectively. In our constant drive for innovation and addressing womens´ intimate health needs, we have expanded our portfolio with the recent additions of innovative products including an over-the-counterself-care treatment for bacterial vaginosis, a self-test for menopause and a self-test for urinary tract infection. By 2024, we anticipate the product portfolio to more than double.

Strategically important partner agreements signed during the quarter open up opportunities for expansive geographical presence. The USA remains our strategically most important market, and our efforts are laser-focused on bolstering our presence in this highly attractive market for intimate self-care. The agreement with Walmart to feature our self-test for bacterial vaginosis under their brand is a significant milestone. Concurrently, efforts to increase sales through CVS and Walgreens are ongoing as well as increasing sales under own brand. These endeavors underscore our unwavering focus and heightened ambition to accelerate growth in the USA, all while maintaining momentum in other strategically chosen markets.

During the quarter, Sweden exhibited robust growth of 91%, driven by both organic growth and a diversification of our product portfolio. The positive trajectory in the Swedish market, our reference market, unmistakably indicates a strong demand for our products. Revenue in our primary business area, Medical Consumer, shows a dip compared to the same quarter of the previous year, attributed to variations in the timing of incoming orders from partners. I anticipate these fluctuations will persist as our distribution agreement-based business model naturally entails volatile sales, however, as we increase our sales volume, we expect further consistency in orders. The decrease in sales within the Lifestyle Consumer business area follows a strategic streamlining of our product offerings and narrowed focus on key markets. However, cost reductions within Lifestyle Consumer have improved our operating results despite the lower sales. Increased costs for the group are attributed one-time merger costs with Pharmiva and one-time efficiency expenditures, such as organizational restructuring,

The merger with Pharmiva not only enriched our portfolio with a bacterial vaginosis treatment but also empowered the organization with expertise in sales, marketing, regulatory affairs, and quality. Our ongoing efforts to streamline operations include the integration of the companies' quality management systems. The phased-out transition of Pharmiva's quality management system aims to avoid duplicate audits from notified bodies* - a strategic decision made to reach expected sales targets for Vernivia while preventing additional strain on our resources.

Together with the organization, our board, and shareholders, I eagerly anticipate continuing to shape a new era in intimate self-care among women. Concurrently, we aim to position Peptonic Medical as an international, cash-flow-positive company. My outlook for 2024 brims with optimism and high expectations.

Anna Linton. CEO

*CE mark of medical devices is regulated within the EU by the medical device directive (MDD), a set of regulations which in 2021 was replaced with Medical Device Regulation (MDR). A notified body is accredited for MDD and or MDR and ensures compliance to the directive's requirements for CE mark.

YEAR END REPORT, 2023

3

ABOUT THE COMPANY

Peptonic Medical AB is an innovative Swedish biomedical company engaged in research, development, and sales of clinically proven self-diagnostic rapid tests and self-care and preventive treatments within women's intimate health. The company's vision is to improve intimate health by providing women with the tools and opportunities to self-diagnose, treat, and prevent medical conditions in the genital area.

The business is divided into two areas, Medical Consumer and Lifestyle Consumer. Medical Consumer offers a unique over-the-counter portfolio of rapid tests and self-care products for the treatment and prevention of medical conditions such as vaginal atrophy, bacterial vaginosis, amniotic fluid leakage, and urinary tract infections. The product portfolio provides a unique comprehensive solution for women in intimate self-care and is sold under the brands VagiVital and Vernivia. The company's other business area, Lifestyle Consumer, focuses on a broader portfolio of sustainable period products sold under the Lunette brand.

Peptonic Medical continuously aims to broaden the company's product portfolio through acquisitions and development of innovative and competitive products in-house. The company's mousse-based drug- delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio. Central to the growth strategy is the geographical expansion of VagiVital through collaboration with local partners, where the USA represents a key market. The goal is to position Peptonic Medical on the international stage and become a leading player in women's intimate self-care according to the concept of diagnose, treat, and prevent.

Share

Peptonic Medical has been listed on the Spotlight Stock Market since 2014 and trades under the ticker symbol: PMED. The share capital of the company amounts to 38,371,139.9 SEK divided into 1,534,845,596 outstanding shares with a nominal value of 0.025 SEK per share. The number of outstanding warrants amounts to 196,370,600. Upon full exercise of the warrants, the number of shares will increase by 196,370,600.

Organization

The group consists of the parent company Peptonic Medical AB (publ) headquartered in Stockholm, Sweden, and its subsidiaries Common Sense, USA, PMI, Israel, and Lune Group Oy, Finland.

At the end of the period, the number of employees in the group amounted to 38 (34), and for the parent company, it was 9 (3) at the end of the period. Of the total employees in the group and the parent company, 4 employees have come from the merger with Pharmiva. In a restructuring, 3 individuals have left the group, including 2 individuals from the parent company.

For further information: www.peptonicmedical.se

YEAR END REPORT, 2023

4

FINANCIAL INFORMATION - GROUP

During the fourth quarter of 2023, the merger with Pharmiva has been integrated into the parent company. Pharmiva's accumulated results before the merger date and most merger-related costs have been directly allocated to equity in the parent company and do not affect the income statement. Starting from the merger date on November 21, Pharmiva is included in the group's operating results and balance sheet. Therefore, the figures for the fourth quarter and full year of 2023 are not directly comparable to 2022 due to the inclusion of the Pharmiva results post the completion of the merger.

Revenue - Revenue for the fourth quarter amounted to 7,159 (11,924) KSEK, of which sales of products accounted for 6,786 (10,191) KSEK. Sales within the Medical Consumer business area amounted to 4,577 (5,862) KSEK, a decrease compared to the same quarter in 2022, mainly explained by the shifting of the timing of orders from distributors, which may vary across quarters. During the fourth quarter of 2022 orders were received from key partners such as Primalabs, Paladin, and Exeltis. Corresponding orders did not materialize during the quarter of 2023 but were deferred to the first quarter of 2024, where they were received.

Sweden as a single market delivered strong growth during the quarter, with sales increasing by 91% compared to the same quarter last year, driven by good organic growth and a continuous expansion of the product portfolio. Sales within the Lifestyle Consumer business area amounted to 2,209 (4,329) KSEK, a decrease compared to the same period the previous year, following a streamlining of the portfolio and increased focus on core markets. However, we have rightsized the costs within the business resulting in improved operating results despite the lower sales.

For the full year 2023, revenues amounted to 38,265 (46,404) KSEK, of which sales of products accounted for 37,118 (43,634) KSEK. Sales within the Medical Consumer business area amounted to 24,596 (24,538) KSEK, and the Lifestyle Consumer business area contributed sales of 12,521 (19,096) KSEK. Also, for the full year, Sweden as a single market has shown strong growth, with turnover increasing by 61%.

Operating expenses - During the fourth quarter, the group's expenses amounted to -26,731(-18,814) KSEK, where comparison-affecting items of non-recurring nature amounted to -7,687 KSEK. These items were driven by personnel restructuring costs (-1,800 KSEK), write-down of an old receivable in the USA (-

885 KSEK), write-down of an oxytocin patent within menopause (-1,986 KSEK), and adjustment of obsolescence amounting to -3,016 KSEK regarding products acquired in connection with the Common Sense acquisition in 2021. Adjusted for comparison-affecting items, the cost of goods sold during the quarter amounted to -3,077 KSEK, resulting in an adjusted gross margin of 55%. Continuous efforts are underway to streamline operations and create synergies following the merger with Pharmiva.

For the full year, the group's expenses amounted to -79,451(-80,010) KSEK, where comparison-affecting items of non-recurring nature amounted to -7,687 KSEK. Adjusted for comparison-affecting items, the year resulted in a gross margin of 52.0%, in line with the previous year.

YEAR END REPORT, 2023

5

Result - The group's result after financial net adjusted for comparison-affecting items amounted to - 11,885 (-7,111) KSEK for the fourth quarter. For the full year, the corresponding adjusted result was - 33,499 (-36,857) KSEK.

Financial position and liquidity - Cash and bank as of December 31, 2023, amounted to 15,134 (3,566) KSEK. The cash flow for the full year 2023 was positive and amounted to 11,568 KSEK. The cash flow from operating activities was negative at -33,808 KSEK. The positive cash flow is explained by the completed new share issue with subsequent subscription options totaling 72,829 KSEK.

Equity - The group's equity as of December 31, 2023, amounted to 75,323 (47,092) KSEK, resulting in a solvency ratio of 71% (55%).

Liabilities - The group's short-term liabilities amounted to 31,414 (38,660) KSEK as of December 31, 2023. Interest-bearing liabilities amount to 16,943 MSEK, of which 8,076 KSEK pertains to deferment with the Swedish Tax Agency and the remainder to a short-term loan. During the fourth quarter, the company obtained a short-term loan totaling just over 8 MSEK. The loan was acquired to provide the company the resources to continue to make necessary short-term investments to capitalize on attractive growth opportunities.

YEAR END REPORT, 2023

6

INCOME STATEMENT
Peptonic Group
		3 mon	3 mon	12 mon	12 mon
		oct-dec	oct-dec	jan-sep	jan-sep
KSEK	Note	2023	2022	2023	2022
Operating income
Sales of products		6 786	10 191	37 118	43 634
Other operating income		372	1 733	1 147	2 770
Total operating income		7 159	11 924	38 265	46 404
Operating expenses
Cost of goods		-6 093	-5 890	-20 823	-20 239
Other external expenses	1	-9 218	-7 405	-28 839	-34 186
Personnel costs	5	-7 619	-4 585	-23 440	-21 922
Depreciation	5	-3 739	-885	-6 266	-3 491
Other operating costs		-63	-49	-83	-172
Total operating expensses		-26 731	-18 814	-79 451	-80 010
Operating loss		-19 572	-6 890	-41 186	-33 606
Items affecting comparability, operating result	5	-7 687
Adjusted operating loss		-11 885
Net financial income		414	0	919	0
Net financial expense		-459	-1 232	-2 323	-3 251
Loss before taxes		-19 617	-8 122	-42 589	-36 857
Adjusted loss before tax excluding items affecting comparabilit	-11 930	-7 111	-34 902	-36 857
Taxes		0	0	0	0
Net loss for the period		-19 617	-8 122	-42 589	-36 857

YEAR END REPORT, 2023

7

BALANCE SHEET
Peptonic Group
		31-dec	31-dec
KSEK	Note	2023	2022
Assets
Non-Current assets
Intangeble assets	2	62 538	50 098
Tangeble assets	3	3 783	4 299
Financial assets		0	0
Total non-current assets		66 321	54 398
Current assets
Stock		16 002	15 368
On going fund raising		0	0
Other receivbles		6 082	8 267
Tax receivable		287	89
Prepaid expenses and accrued income		2 910	4 064
Liquid assets		15 134	3 566
Total current assets		40 415	31 354
Total assets		106 736	85 752
Equity and liabilites
Equity
Ristricted equity
Share capital		38 371	24 274
Ongoing right issues		0	0
Reserves		5 377	7 392
Other contributed capital		333 041	273 613
Profit or loss brought forward incl year result		-301 466	-258 187
Total equity		75 323	47 092
Current liabilites
Liabilities interest bearing		7 556	4 180
Trade payables		13 779	22 881
Other payables		5 580	5 720
Prepaid income and accrued expenses		4 498	5 879
Total current liabilities		31 414	38 660
Total equity and liabilities		106 736	85 752

YEAR END REPORT, 2023

8

STATMENT OF CASH FLOW
Peptonic Group
		12 mon	12 mon
		jan-sep	jan-dec
KSEK	Note	2023	2022
CASH FLOW FROM OPERATIONS BEFORE CHANGES IN WORKING CAPITAL

Operating profit/loss Non-cash flow items Paid tax NET CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL

-	42 589	-	36 857
	7 054		3 491
	-		-
-	35 535	-	33 366

Increase (-) decrease (+) inventory	-	634	-	5 045
Increase (-) decrease (+) receivables		5 176	-	5 810
Increase (-) decrease (+) liabilities	-	2 815	-	357
NET CASH FLOW FROM OPERATING ACTIVITIES	-	33 808	-	44 579
CASH FLOW FROM INVESTING ACTIVITIES
Investment in immaterial assets, net	-	1 285	-	987
Investment in material assest, incl subsidaries	-	646		-
Investment in financial assets, net	-	14 413		-
Divestment / reduction of financial assets	-	2 705		1 184
NET CASH FLOW FROM INVESTING ACTIVITIES	-	19 050		197
CASH FLOW FROM FINANCING ACTIVITIES
Rights issue		87 243		33 704
Issue expenses	-	13 718	-	3 444
Bridgeloan	-	9 101		7 534
NET CASH FLOW FROM FINANCING ACTIVITIES		64 425		37 794
TOTAL CASH FLOW FOR THE YEAR		11 568	-	6 587
Cash and cash equivalents at beginning of period		3 566		10 153
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD		15 134		3 566

YEAR END REPORT, 2023

9

CHANGES IN EQUITY
Peptonic Group
				Share
	Share	Develop-	Ongoing	Premium	Accumul-	Total
	ment cost	reserve	shareholders
	Capital	right issue	ated losses
	fund	non-	equity
KSEK				restricted
Opening balance January 1, 2022	19 164	9 617	0	247 338	-224 102	52 017
Net loss for the year					-36 857	-36 857
Transfering fund		-2 225			2 225	0
Right issue	5 110		0	28 618		33 728
On going right issues					547	547
Issue expenses				-3 444		-3 444
Closing balance December 31, 2022	24 274	7 392	0	272 513	-258 187	45 992
Opening balance January 1, 2023	24 274	7 392	0	272 513	-258 187	45 992
Net loss for the year					-42 589	-42 589
Transfering fund		-2 015			2 015	0
Right issue	14 097			26 667		87 243
On going right issues			0			0
Coneversion difference					-2 705	-2 705
Issue expenses						-13 718
Closing balance December 31, 2023	38 371	5 377	0	299 180	-301 466	74 223

YEAR END REPORT, 2023

10